| This week's sponsor is Premier Research. | |  | Placebo Response: A Real Threat to Pain Trials
Rising placebo response rates skew analgesia clinical trial data and limit treatment options for suffering patients. Learn how to manage this pain point in analgesia trials with our free eBook. Premier Research. It's what we do. Best. |
Today's Rundown Featured Story | | | Monday, December 10, 2018 Axovant has halted development of nelotanserin after it missed the primary endpoint in a phase 2 trial in patients with Lewy body dementia. The lackluster data persuaded Axovant to drop the drug and complete its pivot from small molecules to gene therapies. |
|
|
Top Stories Monday, December 10, 2018 Potential liver-related side effects have led to the FDA placing a partial clinical hold on a MacroGenics-developed bispecific antibody for cancer. Monday, December 10, 2018 Gritstone Oncology has appointed Jonah Rainey, Ph.D., to head up its bispecific antibody program as it moves into lead optimization. Monday, December 10, 2018 Novo Nordisk has enlisted e-therapeutics to support target discovery efforts at its recently opened research center in Oxford, U.K. The collaboration will see e-therapeutics apply its platform for finding synergistic target combinations to a “specific area” of Type 2 diabetes. Monday, December 10, 2018 China’s Junshi Biosciences may follow in compatriot Innovent Biologics’ footsteps as it tees up to raise $414 million in its Hong Kong IPO, Reuters reported. It’s the latest company looking to list on the Hong Kong Stock Exchange after it relaxed its rules for early-stage biotechs. Monday, December 10, 2018 With Gilead Sciences' CEO on the way out and hepatitis C revenues tumbling, the company needs a leader who can pump up in oncology. And hoping to find just that, it has poached a top executive from the biggest cancer drug maker in the world. Resources Sponsored by: Veeva Learn how to spot an imposter with an integrated suite vs. one that’s unified. Read this whitepaper to learn more. Sponsored by: Patheon, part of Thermo Fisher Scientific Read this whitepaper to learn how the biologics market is quickly evolving and how these changes pose several risks to a molecule’s success. Sponsored by: Coupa Software Learn how Becton Dickinson implemented Coupa to create an easy-to-use purchase to pay process that increased efficiency across the organization. Sponsored by: Almac Diagnostic Services, part of the Almac Group Download the whitepaper to learn more. Sponsored by: Reprints Desk, Inc. Learn how to fast-track your research workflows! Sponsored by: Veeva Industry Research: Read the 2018 Unified Clinical Operations Report to find out how pharmas and CROs are evolving clinical trial processes. Sponsored by: Applied BioMath This on-demand webinar introduces a quantitative systems pharmacology (QSP) model of targeted anabolic growth factors for intra-articular injection for the treatment of diseased joints. Sponsored by: Oracle Health Sciences New research reveals more than 50% of clinical data management professionals surveyed, are not confident in the quality and completeness of their clinical trial data. Sponsored by: Veradigm New Case Study – Leveraging Real-World Evidence From EHR to Assess Migraine Management Sponsored by: Signals Analytics What does data tell us about the future of cell & gene therapy? Sponsored by: Outer Edge Technology Outer Edge Technology specializes in designing and managing regulated cloud-based infrastructures for the Life Sciences Industry – typically leveraging the AWS and Microsoft Azure platforms. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. | 
.jpg/Pavan%20headshot%20(1).jpg/56b3097413ac509cc9e7fb03b2a3ae26)
